Aptevo Therapeutics Inc (NASDAQ:APVO) was the target of a significant decrease in short interest in the month of December. As of December 15th, there was short interest totalling 357,460 shares, a decrease of 46.2% from the November 30th total of 664,081 shares. Based on an average trading volume of 441,879 shares, the days-to-cover ratio is currently 0.8 days. Approximately 2.1% of the company’s shares are short sold.

Shares of Aptevo Therapeutics (NASDAQ APVO) opened at $4.65 on Thursday. Aptevo Therapeutics has a 12 month low of $1.15 and a 12 month high of $4.85. The firm has a market cap of $99.43 and a price-to-earnings ratio of -2.55. The company has a quick ratio of 7.67, a current ratio of 7.76 and a debt-to-equity ratio of 0.19.

In other news, VP Randy Joe Maddux bought 25,000 shares of Aptevo Therapeutics stock in a transaction dated Wednesday, November 15th. The shares were acquired at an average price of $2.76 per share, with a total value of $69,000.00. Following the completion of the purchase, the vice president now owns 25,000 shares in the company, valued at approximately $69,000. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 15.60% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Dimensional Fund Advisors LP grew its holdings in shares of Aptevo Therapeutics by 8.0% in the second quarter. Dimensional Fund Advisors LP now owns 1,056,729 shares of the biotechnology company’s stock worth $2,187,000 after purchasing an additional 78,109 shares during the last quarter. Legal & General Group Plc grew its holdings in shares of Aptevo Therapeutics by 11,751.3% in the second quarter. Legal & General Group Plc now owns 393,701 shares of the biotechnology company’s stock worth $815,000 after purchasing an additional 390,379 shares during the last quarter. Finally, Precept Management LLC bought a new position in shares of Aptevo Therapeutics in the second quarter worth about $1,210,000. Hedge funds and other institutional investors own 32.13% of the company’s stock.

Several brokerages have recently weighed in on APVO. ValuEngine raised shares of Aptevo Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Wednesday, September 6th. Piper Jaffray Companies reissued an “overweight” rating and issued a $6.00 target price on shares of Aptevo Therapeutics in a research note on Thursday, October 5th.

TRADEMARK VIOLATION NOTICE: This news story was originally published by Daily Political and is the property of of Daily Political. If you are reading this news story on another domain, it was stolen and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://www.dailypolitical.com/2018/01/04/aptevo-therapeutics-inc-apvo-sees-large-decrease-in-short-interest.html.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics Inc is a biotechnology company. The Company is focused on oncology and hematology therapeutics. The Company is engaged in the discovery, development, commercialization and sale of oncology and hematology therapeutics. The Company’s technology is the ADAPTIR (modular protein technology) platform.

Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.